Literature DB >> 11745393

Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro.

H Beck1, G Schwarz, C J Schröter, M Deeg, D Baier, S Stevanovic, E Weber, C Driessen, H Kalbacher.   

Abstract

The biochemical characterization of antigen degradation is an important basis for a better understanding of both the immune response and autoimmune diseases mediated by MHC class II molecules. In this study we used high-performance liquid chromatography and mass spectrometry to analyze the processing of myelin basic protein (MBP), a potential autoantigen implicated in the pathogenesis of multiple sclerosis. We resolved the kinetics of MBP processing by lysosomal extracts or purified endocytic proteases, identified the major cleavage sites during this process and assigned them to the activity of proteolytic enzymes. Proteolytic processing of MBP is mostly guided along the hydrophobic regions of the protein. It is initiated by two proteolytic steps (after N(92) and S(110)) that are performed by an asparagine-specific endopeptidase (AEP) and by cathepsin (Cat) S, respectively. The resulting processing intermediates are converted into more than 60 different species of 20-40-mers due to the activity of endopeptidases including CatS, D and L. The fragments thus generated are subsequently degraded by C- or N-terminal trimming. Strikingly, the initial cleavages during MBP processing affect two immunodominant regions of the potential autoantigen [MBP(85-99) and MBP(111-129)] in an inverse manner. CatS directly generates the N terminus of the epitope MBP(111-129) in large quantities during the initial phase of processing, which might explain the immunogenicity of this region in spite of its relatively poor binding to HLA-DR4. In contrast, the dominant cleavage by AEP mediates the destruction of MBP(85-99) unless the epitope is protected, e.g. by binding to HLA-DR. Our results thus characterize the proteolytic events during processing of MBP on a molecular level and suggest a biochemical basis for the immunogenicity of the immunodominant epitopes, which could serve as a guideline for future therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745393     DOI: 10.1002/1521-4141(200112)31:12<3726::aid-immu3726>3.0.co;2-o

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  26 in total

1.  Autophagy promotes MHC class II presentation of peptides from intracellular source proteins.

Authors:  Jörn Dengjel; Oliver Schoor; Rainer Fischer; Michael Reich; Marianne Kraus; Margret Müller; Katharina Kreymborg; Florian Altenberend; Jens Brandenburg; Hubert Kalbacher; Roland Brock; Christoph Driessen; Hans-Georg Rammensee; Stefan Stevanovic
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-13       Impact factor: 11.205

2.  Myelin-reactive type B T cells and T cells specific for low-affinity MHC-binding myelin peptides escape tolerance in HLA-DR transgenic mice.

Authors:  Kazuyuki Kawamura; Katherine A McLaughlin; Robert Weissert; Thomas G Forsthuber
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

3.  The effect of haptens on protein-carrier immunogenicity.

Authors:  Tal Gefen; Jacob Vaya; Soliman Khatib; Irena Rapoport; Meital Lupo; Eilon Barnea; Arie Admon; Elimelech Dan Heller; Elina Aizenshtein; Jacob Pitcovski
Journal:  Immunology       Date:  2015-01       Impact factor: 7.397

4.  Analysis of gene expression in MOG-induced experimental autoimmune encephalomyelitis after treatment with a novel brain-penetrating antioxidant.

Authors:  Yossi Gilgun-Sherki; Yael Barhum; Daphne Atlas; Eldad Melamed; Daniel Offen
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

5.  Mice deficient in endothelin-converting enzyme-2 exhibit abnormal responses to morphine and altered peptide levels in the spinal cord.

Authors:  Lydia K Miller; Xiaowen Hou; Ramona M Rodriguiz; Khatuna Gagnidze; Jonathan V Sweedler; William C Wetsel; Lakshmi A Devi
Journal:  J Neurochem       Date:  2011-11-01       Impact factor: 5.372

6.  Interferon-gamma regulates cathepsin G activity in microglia-derived lysosomes and controls the proteolytic processing of myelin basic protein in vitro.

Authors:  Timo Burster; Alexander Beck; Simone Poeschel; Anita Øren; Daniel Baechle; Michael Reich; Olaf Roetzschke; Kirsten Falk; Bernhard O Boehm; Sawsan Youssef; Hubert Kalbacher; Herman Overkleeft; Eva Tolosa; Christoph Driessen
Journal:  Immunology       Date:  2007-02-14       Impact factor: 7.397

7.  Quantifying cathepsin S activity in antigen presenting cells using a novel specific substrate.

Authors:  Nicolas Lützner; Hubert Kalbacher
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

Review 8.  Cysteine cathepsins in neurological disorders.

Authors:  Anja Pišlar; Janko Kos
Journal:  Mol Neurobiol       Date:  2013-11-15       Impact factor: 5.590

Review 9.  Asparagine endopeptidase is an innovative therapeutic target for neurodegenerative diseases.

Authors:  Zhentao Zhang; Manling Xie; Keqiang Ye
Journal:  Expert Opin Ther Targets       Date:  2016-05-13       Impact factor: 6.902

Review 10.  Cathepsin G: roles in antigen presentation and beyond.

Authors:  Timo Burster; Henriette Macmillan; Tieying Hou; Bernhard O Boehm; Elizabeth D Mellins
Journal:  Mol Immunol       Date:  2009-11-11       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.